Clomiphene (Clomid) for Men: TRT Alternative, Dosing, and How It Compares to Testosterone Injections

What Is Clomiphene and Why Do Men Take It?

Clomiphene citrate is a selective estrogen receptor modulator that blocks estrogen receptors in the hypothalamus, tricking the brain into thinking estrogen is low and prompting a surge in gonadotropin-releasing hormone (GnRH), then LH and FSH. The testes respond by producing more testosterone and, importantly, continuing to make sperm. That fertility-preserving property is the main reason men with secondary hypogonadism who want children choose clomiphene over testosterone injections.

The drug carries FDA approval only for inducing ovulation in women, but its mechanism translates directly to men with secondary (central) hypogonadism, a condition in which the testes are capable of producing testosterone but receive insufficient pituitary signaling. Off-label prescribing for this indication is well-supported in the literature and widely endorsed by urologists and endocrinologists. A 2019 clinical practice guideline from the American Urological Association explicitly lists clomiphene citrate as a fertility-preserving option for hypogonadal men who wish to maintain sperm production. [1]

Exogenous testosterone, whether as testosterone cypionate, testosterone enanthate, testosterone propionate, or subcutaneous pellets, replaces the body's own hormone but signals the pituitary to shut down LH and FSH production. Within 4-12 weeks of starting standard TRT, sperm counts typically fall toward azoospermia in most men. Clomiphene sidesteps that problem entirely.

How Clomiphene Raises Testosterone: The Mechanism

The hypothalamic-pituitary-gonadal (HPG) axis runs on a feedback loop. Estrogen and testosterone at the hypothalamus signal the system to quiet down. Clomiphene binds estrogen receptors at the hypothalamus and anterior pituitary without activating them, so the feedback brake is removed. GnRH pulse frequency increases, LH and FSH rise, and the Leydig cells in the testes ramp up testosterone synthesis.

A prospective study published in the Journal of Urology (Katz et al., 2012, N=86) found that 50 mg clomiphene citrate administered every other day raised mean total testosterone from 247 ng/dL to 610 ng/dL over a median follow-up of 19 months, with 96.5% of patients achieving a testosterone level above 300 ng/dL. [2] The LH-to-FSH ratio remained intact, meaning testicular function was actively stimulated rather than bypassed.

Because clomiphene also raises LH in men with retained pituitary function, it cannot work in primary hypogonadism (Klinefelter syndrome, post-orchidectomy, radiation damage to the testes). The pituitary-to-testis signaling chain must be functional. A morning total testosterone below 300 ng/dL combined with low or low-normal LH confirms the secondary pattern that clomiphene targets.

Clomiphene Dosing Protocols for Men

Dosing is not one-size-fits-all. Standard published protocols fall into three ranges. [3]

Low-dose daily: 25 mg per day. Produces modest, steady testosterone elevation with less estradiol rise. Favored for older men or those sensitive to estrogen side effects like gynecomastia.

Every-other-day dosing: 25-50 mg every 48 hours. The most common regimen in the published literature. Mimics the intermittent pulse pattern of LH, which some data suggest produces a more physiologic testosterone-to-estradiol ratio than continuous daily dosing.

Higher-dose protocols: 50 mg daily. Used when response at 25 mg is insufficient. Carries a higher risk of visual disturbances and excess estradiol elevation; the Endocrine Society 2018 guidelines caution that estradiol should be monitored closely above this dose range. [4]

Labs should be repeated at 6-8 weeks after any dose initiation or adjustment: total testosterone (drawn in the morning), LH, FSH, estradiol (sensitive assay), and a CBC to check hematocrit. Unlike testosterone cypionate, clomiphene does not significantly raise hematocrit, which removes one of the most common monitoring burdens of injection-based TRT.

Clomiphene vs. Testosterone Cypionate: A Direct Comparison

Testosterone cypionate is the most prescribed testosterone ester in the United States. Standard TRT dosing runs 100-200 mg intramuscularly or subcutaneously every 7-14 days, producing trough testosterone levels typically in the 400-700 ng/dL range, with peaks that can briefly exceed 1 to 000 ng/dL after injection. The peak-to-trough swing is one of the most cited complaints from men on weekly cypionate: energy and mood can mirror the injection cycle.

Clomiphene, by contrast, produces a steadier testosterone elevation without peaks. The testosterone level achieved is generally lower, typically 450-650 ng/dL, and because it is generated endogenously, it does not suppress LH and FSH. The practical consequences of that difference are significant. Testicular volume is maintained with clomiphene; within 3-6 months of starting testosterone cypionate, testicular atrophy develops in the majority of men due to the absence of LH stimulation. [5]

From a cardiovascular standpoint, a 2020 review in Translational Andrology and Urology noted that clomiphene does not raise hematocrit to the degree that exogenous testosterone does, reducing the theoretical risk of polycythemia-related thrombosis. [6] Testosterone cypionate at doses above 150 mg/week raises hematocrit above 50% in approximately 15-20% of men, which is why the American Urological Association 2018 TRT guidelines recommend pausing therapy if hematocrit exceeds 54%. [1]

| Feature | Clomiphene 25-50 mg | Testosterone Cypionate 100-200 mg/wk | |---|---|---| | Route | Oral | IM or subcutaneous injection | | Fertility preserved | Yes | No (azoospermia risk) | | HPG axis | Stimulated | Suppressed | | Testosterone range | 450-650 ng/dL typical | 400-1,000+ ng/dL (peak-dependent) | | Hematocrit rise | Minimal | Moderate (15-20% exceed 50%) | | Testicular atrophy | No | Yes, 3-6 months onset | | Cost (monthly) | $30-$80 | $40-$120 (plus supplies) | | FDA approval for men | Off-label | Yes (hypogonadism) |

Clomiphene vs. Testosterone Enanthate

Testosterone enanthate and testosterone cypionate are pharmacologically nearly identical. Both are long-acting esterified testosterone dissolved in oil; enanthate has a half-life of roughly 4.5 days versus cypionate's 8 days, meaning enanthate produces a slightly faster peak and drops off a bit sooner. In clinical practice, most physicians treat them as interchangeable for TRT purposes, and a 2021 review in Andrology confirmed no statistically significant difference in symptom outcomes between the two esters at equivalent doses. [7]

The comparison to clomiphene follows the same logic as the cypionate comparison above. Enanthate is injected, suppresses the HPG axis, and achieves higher peak testosterone values than clomiphene can. Men who need testosterone above 700 ng/dL to resolve symptoms, or who have primary hypogonadism, will not achieve that target with clomiphene. Men who are planning to conceive within 12-24 months have a strong reason to prefer clomiphene or to combine low-dose clomiphene with hCG rather than start enanthate.

Clomiphene vs. Testosterone Propionate and Pellets

Testosterone propionate is a short-acting ester with a half-life of roughly 0.8-1.5 days. It requires injections every 1-3 days to maintain stable levels. Its main contemporary use is in compounded formulations for men who want more frequent, smaller doses to minimize peaks, or in specific protocols that require fast washout. Most men on propionate inject 50-100 mg every 2-3 days. The injection burden is substantially higher than cypionate or enanthate, and like those esters, propionate fully suppresses HPG output.

Testosterone pellets (e.g., Testopel, 75 mg pellets implanted subcutaneously) are inserted into the hip or buttock under local anesthesia and dissolve over 3-6 months. Published data on Testopel show mean testosterone levels of 567 ng/dL at 6 months in hypogonadal men, which is comparable to clomiphene but delivered exogenously, with the same fertility consequences as any other form of exogenous testosterone. [8] Pellets appeal to men who want zero weekly administration burden. Clomiphene, at once-daily or every-other-day oral dosing, is lower burden than injections but still requires daily adherence.

Who Is the Right Candidate for Clomiphene?

The following clinical profile fits clomiphene well. Total testosterone confirmed below 300 ng/dL on two morning draws. LH normal or low-normal (not elevated, which would indicate primary failure). FSH either normal or low. Active desire to preserve fertility or avoid injections. No history of bilateral anorchia, orchidectomy, or testicular radiation. Absence of pituitary tumor (MRI recommended when LH and FSH are both very low to rule out a prolactinoma or macroadenoma before starting clomiphene).

Men who should not use clomiphene include those with primary hypogonadism (elevated LH and FSH, meaning the testes cannot respond even with more stimulation), those with confirmed visual symptoms from prior SERM use, and men with known hypersensitivity to the compound.

The Endocrine Society's 2018 clinical practice guideline on male hypogonadism states: "We suggest fertility-sparing alternatives such as clomiphene citrate or human chorionic gonadotropin be considered in men who wish to maintain their fertility." [4]

A secondary consideration is patient preference around needles and injection logistics. Clomiphene eliminates sharps disposal, the need to keep vials refrigerated, and the injection-site reactions that affect a portion of men on oil-based testosterone formulations.

Monitoring and Managing Side Effects

Clomiphene is generally well-tolerated in men. The most clinically meaningful side effects are:

Estradiol elevation. Because clomiphene raises LH, Leydig cells produce more testosterone, and aromatase converts a portion of that to estradiol. In a subset of men, estradiol climbs above 40-42 pg/mL (sensitive assay), producing nipple tenderness or mild gynecomastia. A dose reduction to 12.5-25 mg every other day usually resolves this without requiring an aromatase inhibitor.

Visual disturbances. Blurred vision or visual field changes occur in a small percentage of patients, primarily at 50 mg/day and above. This side effect is reversible on discontinuation but is an absolute reason to stop the drug and consult ophthalmology. The incidence in the male TRT literature is considerably lower than reported in the original female fertility studies, likely because the doses used in men are lower.

Mood effects. Some men report irritability or mood flattening. A 2019 comparative study (Ramasamy et al., N=198) found that men treated with clomiphene had significantly improved sexual function scores (IIEF scores rose from a median of 17 to 25, P<0.001) with a side-effect profile favorable to topical testosterone gel. [9]

Labs at baseline and at 6-8 weeks after initiation: total testosterone (morning fasting), free testosterone (calculated or equilibrium dialysis), LH, FSH, estradiol (sensitive LC-MS/MS assay), CBC, metabolic panel. Repeat annually once stable.

Combining Clomiphene with HCG

For men who want to preserve testicular size and fertility while achieving testosterone levels closer to the cypionate range, some clinicians use clomiphene alongside low-dose human chorionic gonadotropin (hCG). HCG directly mimics LH at the Leydig cell, adding testosterone output on top of what clomiphene stimulates. A typical add-on protocol is 500-1 to 000 IU hCG two to three times per week subcutaneously. This combination is used off-label but has clinical support in the fertility literature.

Published data from a 2013 study in Fertility and Sterility (Hussein et al., N=103) found that combination clomiphene plus hCG normalized testosterone and improved sperm parameters in 95% of men with secondary hypogonadism after 6 months of treatment, compared to 74% improvement with clomiphene alone. [10]

Transitioning From Testosterone Injections to Clomiphene

Men already on testosterone cypionate or enanthate who want to restore fertility face a recovery period. After stopping exogenous testosterone, the HPG axis takes an average of 3-6 months to resume spontaneous function, though full sperm recovery may take 12-24 months in some cases. Clomiphene is commonly started 4-6 weeks after the last testosterone injection to accelerate pituitary recovery, often alongside hCG during the first 2-3 months to support Leydig cell function while endogenous LH returns.

Testosterone levels should be checked every 4 weeks during this transition to confirm the axis is recovering. Starting clomiphene too early, before exogenous testosterone has cleared, produces artificially elevated feedback that blunts the initial LH response.

Regulatory Status and Prescribing Considerations

Clomiphene citrate is FDA-approved (NDA 016131) for female ovulatory dysfunction. Male use is off-label under 21 CFR provisions that permit physicians to prescribe approved drugs for unlabeled indications when supported by clinical evidence. [11] A valid prescription from a licensed provider is required. Generic clomiphene is available from most compounding and retail pharmacies at $30-$80 per month for a 25-50 mg daily regimen, making it one of the most cost-accessible options in the hypogonadism treatment space.

Clomiphene is not a controlled substance in the United States, unlike testosterone cypionate and testosterone enanthate, which are Schedule III controlled substances under the Controlled Substances Act. This distinction simplifies prescribing logistics: no DEA registration is required, and prescriptions may be refilled without the 90-day restriction that applies to Schedule III hormones in most states.